NTSR2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2039247	0.69	19/20
SCHEMBL2039240	0.68	19/20
SCHEMBL8420900	0.62	19/20
SCHEMBL9507556	0.58	19/20
SCHEMBL9540745	0.65	18/20
SCHEMBL8813616	0.57	18/20
SCHEMBL2195159	0.53	18/20
SCHEMBL9543572	0.73	17/20
Hydrochloric Acid (SCHEMBL9540881)	0.71	17/20
Hydrochloric Acid (SCHEMBL9543484)	0.61	17/20
SCHEMBL8741230	0.59	17/20
SCHEMBL10592955	0.64	16/20
SCHEMBL8225101	0.56	16/20
SCHEMBL8418325	0.55	16/20
SCHEMBL2195145	0.52	16/20
SCHEMBL9807233	0.47	16/20
SCHEMBL9540813	0.64	15/20
SCHEMBL6232455	0.64	15/20
SCHEMBL6232463	0.64	15/20
SCHEMBL7461158	0.64	15/20

Clinical trials — most relevant to NTSR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder	PHASE4	COMPLETED
Medication, Weight Gain and GI Hormones	PHASE4	COMPLETED
Comp Granisetron Midazolam Comb in Lap Children	PHASE3	UNKNOWN
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy	PHASE1/PHASE2	RECRUITING
Effects of Exenatide on Hypothalamic Obesity	PHASE1/PHASE2	COMPLETED
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment	PHASE1/PHASE2	RECRUITING
Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease	PHASE2	COMPLETED
Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women	PHASE1	COMPLETED
Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy	PHASE1	WITHDRAWN
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.	nan	UNKNOWN
Humidification in Laparoscopic Colonic Surgery	nan	COMPLETED
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma	nan	COMPLETED
Gastric Activity and Gastrointestinal Peptides in Patients With Functional Dyspepsia	nan	COMPLETED
Neurotensin - an Important Regulator of Appetite in Humans?	nan	UNKNOWN
Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemic Stroke	nan	RECRUITING
Study of the Effect of Antidepressant Drugs on Neurotrophic Factors in Patients With Depression	nan	COMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment	nan	NOT_YET_RECRUITING
A Study on the Effects of Combined FMT on Gut Microbiota and Eating Disorder Symptoms in AN	nan	NOT_YET_RECRUITING
Association of Urine BDNF and NGF With Lower Urinary System Parameters	nan	RECRUITING
Gastrointestinal Hormonal Regulation of Obesity	nan	COMPLETED
Alterations of Gut Microbiome in the Frontline Medical Staff Under the Stress	nan	COMPLETED
RCT to Describe the Effects of Colon Delivered Acetate, Propionate and Butyrate on Satiety and Glucose Homeostasis	nan	COMPLETED
Investigating Optimal Propionate Delivery to the Colon Using Stable Isotope Labeling	nan	COMPLETED
Facilitated Release of Endogenous Enterokines	nan	COMPLETED
Mindfulness in Chronic Kidney Disease	nan	RECRUITING
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NTSR2 binder may also engage these)

Protein	Name	Similarity
Q63384	—	0.997	Q63384 →
P70310	—	0.996	P70310 →
NTSR1	Neurotensin receptor type 1	0.983	landscape →
NMUR1	Neuromedin-U receptor 1	0.982	landscape →
O55040	—	0.982	O55040 →
Q9JJI5	—	0.981	Q9JJI5 →
GALR2	Galanin receptor type 2	0.979	landscape →
Q9XT57	—	0.978	Q9XT57 →
Q95252	—	0.978	Q95252 →
Q9XT58	—	0.977	Q9XT58 →
ADRB3	Beta-3 adrenergic receptor	0.977	landscape →
P26255	—	0.977	P26255 →
O88319	—	0.977	O88319 →
P34971	—	0.976	P34971 →
Q924U1	—	0.976	Q924U1 →
P31387	—	0.976	P31387 →
Q60483	—	0.975	Q60483 →
P25962	—	0.975	P25962 →
P20789	—	0.975	P20789 →
Q9TST4	—	0.975	Q9TST4 →
Q8BL07	—	0.974	Q8BL07 →
Q91V45	—	0.974	Q91V45 →
Q3ZC80	—	0.974	Q3ZC80 →
P46626	—	0.974	P46626 →
Q7TQN7	—	0.974	Q7TQN7 →
MTNR1B	Melatonin receptor type 1B	0.974	landscape →
Q8C206	—	0.973	Q8C206 →
LPAR5	Lysophosphatidic acid receptor 5	0.973	landscape →
Q28524	—	0.973	Q28524 →
O08726	—	0.973	O08726 →